The Memo: Earflo Giving Families an Option Before Surgery

Under the direction of Co-Founder and CEO Intan Oldakowska, PhD, Earflo has brought to market an FDA-cleared, at-home medical device designed to treat the negative middle ear pressure that leads to fluid buildup and chronic ear infections and avoid the path toward surgery. By transforming treatment into something as familiar as drinking from a sippy cup, Earflo aims to address one of the most common pediatric conditions with a solution that is non-invasive, child-friendly, and designed for use at home. Following FDA clearance and a U.S. commercial launch, the company is now focused on expanding access for families while building evidence that earlier intervention can improve quality of life for both children and parents and help avoid ear tube surgery.

Origin Story

Earflo traces its roots to the Stanford Biodesign program, where innovators are trained to identify significant unmet clinical needs before ever thinking about solutions. For Oldakowska and her future co-founders, that process led them to a problem affecting millions of children worldwide: Eustachian tube dysfunction and the chronic ear infections that often follow.

“The project started through the Stanford Biodesign program,” Oldakowska said. “The focus of that program is giving innovators the tools to understand a clinical unmet need and then work toward a solution that can improve patient outcomes.”

During the program, the team observed clinicians in ear, nose, and throat departments and evaluated hundreds of potential needs. One stood out.

“These young children, often under the age of five, can develop ear infections that cause the Eustachian tube to become stuck closed,” Oldakowska explained. “When that happens, fluid builds up behind the eardrum, and it stops them from hearing.”

For children at such a critical stage of development, hearing loss can quickly become more than an ear health issue.

“The issue is that if they can’t hear, they can’t learn,” she said. “These children can experience speech delays, developmental delays, trouble learning at school, difficulty socializing with their peers, sleep issues, and behavioral problems due to pain.”

The founding team brought together expertise from multiple disciplines. Oldakowska and Matt Oldakowski, PhD, contributed engineering and product development experience. Peter Santa Maria, MD, PhD, brought clinical expertise as an ENT surgeon. Stephen Kargotich, PhD, added finance, legal, and commercialization experience. Together, they built Earflo around a shared goal: creating a better option for families navigating a condition that frequently leaves parents with little to do except wait until surgery becomes the only option.

The Current Landscape

Negative middle ear pressure and fluid buildup behind the eardrum represent one of the most common pediatric health concerns. According to studies undertaken at daycares, approximately one in five preschool-aged children is affected at any given time, and the condition contributes to millions of pediatric visits each year.

For many families, the treatment pathway has remained largely unchanged. Children are often monitored through a period of watchful waiting in the hope that the condition resolves naturally. If it does not, ear tube surgery frequently becomes the next step.

“Parents are often told to wait a few months to see if the condition resolves on its own, while their children continue to suffer,” Oldakowska said. “If waiting does not work, the next step is often ear tube surgery.”

The scale of the issue is significant. Oldakowska noted that ear tube placement is the most common pediatric surgery in the United States, with nearly one million procedures performed annually.

For Earflo, the opportunity lies in providing an earlier intervention that can be used at home while families and clinicians determine the best path forward.

“Earflo is designed to help families manage their child’s condition in the convenience of their own home and give them an option they can use immediately,” Oldakowska said. “Right now, many families are told to wait, potentially until surgery. We want to empower parents to help their children sooner with a fun, child-friendly design.”

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-earflo-giving-families-an-option-before-surgery

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more